Structure-guided discovery of a single-domain antibody agonist against human apelin receptor

55Citations
Citations of this article
115Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Developing antibody agonists targeting the human apelin receptor (APJ) is a promising therapeutic approach for the treatment of chronic heart failure. Here, we report the structure-guided discovery of a single-domain antibody (sdAb) agonist JN241-9, based on the cocrystal structure of APJ with an sdAb antagonist JN241, the first cocrystal structure of a class A G protein–coupled receptor (GPCR) with a functional antibody. As revealed by the structure, JN241 binds to the extracellular side of APJ, makes critical contacts with the second extracellular loop, and inserts the CDR3 into the ligand-binding pocket. We converted JN241 into a full agonist JN241-9 by inserting a tyrosine into the CDR3. Modeling and molecular dynamics simulation shed light on JN241-9–stimulated receptor activation, providing structural insights for finding agonistic antibodies against class A GPCRs.

Cite

CITATION STYLE

APA

Ma, Y., Ding, Y., Song, X., Ma, X., Li, X., Zhang, N., … Zhang, M. Y. (2020). Structure-guided discovery of a single-domain antibody agonist against human apelin receptor. Science Advances, 6(3). https://doi.org/10.1126/sciadv.aax7379

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free